Other instances of SWI/SNF acting as a tumor suppressor comes from the heterozygous deletion of BAF47 or alteration of BAF47. These instances result in cases of chronic and acute CML and in rarer cases, Hodgkin's lymphoma, respectively. To prove that BAF47, also known as SMARCB1, acts as a tumor suppressor, experiments resulting in the formation of rhabdoid tumors in mice were conducted via total knockout of BAF47.
Additionally, SWI/SNF acting as a tumor suppressor is observed in instances where there is a heterozygous deletion or mutation of BAF47. This can cause chronic and acute CML, along with rare cases of Hodgkin's lymphoma. To prove that SMARCB1 (also known as BAF47) acts as a tumor suppressor, researchers conducted experiments in mice where BAF47 was completely eliminated, resulting in the development of rhabdoid tumors.